An evaluation of encorafenib for the treatment of melanoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351(10):998–1012.
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the american joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492.
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Neuber K, Kamanabrou D, et al. Combination chemotherapy with or without s.C. Il-2 and IFN-alpha: results of a prospectively randomized trial of the cooperative advanced malignant melanoma chemoimmunotherapy group (acimm). Br J Cancer. 2002;86(2):179–184.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
   PubMed Web of Science ®Google Scholar
• Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (keynote-006). Lancet. 2017;390(10105):1853–1862.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356.
   PubMed Web of Science ®Google Scholar
• Nikolaou VA, Stratigos AJ, Flaherty KT, et al. Melanoma: new insights and new therapies. J Invest Dermatol. 2012;132(3 Pt 2):854–863.
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 2013;49(6):1297–1304.
   PubMed Web of Science ®Google Scholar
• Shtivelman E, Davies MQ, Hwu P, et al. Pathways and therapeutic targets in melanoma. Oncotarget. 2014;5(7):1701–1752.
   PubMed Web of Science ®Google Scholar
• Tsao H, Chin L, Garraway LA, et al. Melanoma: from mutations to medicine. Genes Dev. 2012;26(11):1131–1155.
   PubMed Web of Science ®Google Scholar
• Akbani EA. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–1696.
   PubMed Web of Science ®Google Scholar
• Harding JJ, Catalanotti F, Munhoz RR, et al. A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases. Oncologist. 2015;20(7):789–797.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Amaravadi RK, McArthur GA, et al. Long-term outcome in BRAF(v600e) melanoma patients treated with vemurafenib: patterns of disease progression and clinical management of limited progression. Eur J Cancer. 2015;51(11):1435–1443.
   PubMed Web of Science ®Google Scholar
• McArthur GA, Maio M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol. 2017;28(3):634–641.
   PubMed Web of Science ®Google Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(v600e) and BRAF(v600k) mutation-positive melanoma (brim-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–332.
   PubMed Web of Science ®Google Scholar
• Sloot S, Chen YA, Zhao X, et al. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer. 2018;124(2):297–305.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
   PubMed Web of Science ®Google Scholar
• Broman KK, Dossett LA, Sun J, et al. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Expert Opin Drug Saf. 2019;18(5):381-392.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(v600e) inhibition by rtk or n-ras upregulation. Nature. 2010;468(7326):973–977.
   PubMed Web of Science ®Google Scholar
• Su F, Viros A, Milagre C, et al. Ras mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–215.
   PubMed Web of Science ®Google Scholar
• Holderfield M, Deuker MM, McCormick F, et al. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455–467.
   PubMed Web of Science ®Google Scholar
• Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013;31(14):1767–1774.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. Pubchem Encorafenib, CID: 50922675. [cited 2019 Jun 23]. https://pubchem.ncbi.nlm.nih.gov/compound/Encorafenib
   Google Scholar
• U.S. Food and Drug Administration. Braftovi™ (encorafenib) capsules: U.S. Prescribing information Reference ID: 4283598. [cited 2019 Jun 19]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf (7/19/2019)
   Google Scholar
• Delord JP, Robert C, Nyakas M, et al. Phase i dose-escalation and -expansion study of the BRAF inhibitor encorafenib (lgx818) in metastatic BRAF-mutant melanoma. Clin Cancer Res. 2017;23(18):5339–5348.
   PubMed Web of Science ®Google Scholar
• Nazarian RM, Prieto VG, Elder DE, et al. Melanoma biomarker expression in melanocytic tumor progression: A tissue microarray study. J Cutan Pathol. 2010;37(Suppl 1):41–47.
   PubMedGoogle Scholar
• Sondergaard JN, Nazarian R, Wang Q, et al. Differential sensitivity of melanoma cell lines with brafv600e mutation to the specific RAF inhibitor plx4032. J Transl Med. 2010;8:39.
   Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (columbus): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–615.
   PubMed Web of Science ®Google Scholar
• Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(4):367–402.
   PubMed Web of Science ®Google Scholar
• Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018;30(2):125–133.
   PubMed Web of Science ®Google Scholar
• Wang J, Gan C, Sparidans RW, et al. P-glycoprotein (mdr1/abcb1) and breast cancer resistance protein (bcrp/abcg2) affect brain accumulation and intestinal disposition of encorafenib in mice. Pharmacol Res. 2018;129: 414–423.
   PubMed Web of Science ®Google Scholar
• Adelmann CH, Ching G, Du L, et al. Comparative profiles of braf inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget. 2016;7(21):30453–30460.
   PubMed Web of Science ®Google Scholar
• Sun J, Zager JS, Eroglu Z. Encorafenib/binimetinib for the treatment of braf-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. Onco Targets Ther. 2018;11:9081–9089.
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Keilholz U, Gilles E, et al. Ldh correlation with survival in advanced melanoma from two large, randomised trials (oblimersen gm301 and eortc 18951). Eur J Cancer. 2009;45(10):1807–1814.
   PubMed Web of Science ®Google Scholar
• Smalley KSM, Forsyth PA. The blood brain barrier and BRAF inhibitors: implications for patients with melanoma brain metastases. Pharmacol Res. 2018;135:265–267.
   PubMed Web of Science ®Google Scholar
• Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(v600)-mutant melanoma brain metastases (combi-mb): A multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863–873.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF val600-mutation-positive melanoma (combi-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389–1398.
   PubMed Web of Science ®Google Scholar
• Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic braf v600e/k-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–1639.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(v600)-mutant melanoma (cobrim): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260.
   PubMed Web of Science ®Google Scholar
• Pelster MS, Amaria RN. Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther Adv Med Oncol. 2019;11: 1758835919830826.
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Long GV, Howle JR, et al. Selective braf inhibitors induce marked t-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18(5):1386–1394.
   PubMed Web of Science ®Google Scholar
• Kakavand H, Wilmott JS, Menzies AM, et al. Pd-l1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin Cancer Res. 2015;21(14):3140–3148.
   PubMed Web of Science ®Google Scholar
• Kakavand H, Vilain RE, Wilmott JS, et al. Tumor pd-l1 expression, immune cell correlates and pd-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol. 2015;28(12):1535–1544.
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225–1231.
   PubMed Web of Science ®Google Scholar
• Cooper ZA, Frederick DT, Ahmed Z, et al. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology. 2013;2(5):e24320.
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Haydu LE, Menzies AM, et al. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during braf inhibitor treatment. J Immunol. 2014;192(5):2505–2513.
   PubMed Web of Science ®Google Scholar
• Schilling B, Paschen A. Immunological consequences of selective BRAF inhibitors in malignant melanoma: neutralization of myeloid-derived suppressor cells. Oncoimmunology. 2013;2(8):e25218.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Ferrucci PF, Fisher R, et al. Dabrafenib, trametinib and pembrolizumab or placebo in braf-mutant melanoma. Nat Med. 2019;25(6):941–946.
   PubMed Web of Science ®Google Scholar
• Yao Z, Gao Y, Su W, et al. Raf inhibitor plx8394 selectively disrupts BRAF dimers and ras-independent BRAF-mutant-driven signaling. Nat Med. 2019;25(2):284–291.
   PubMed Web of Science ®Google Scholar